Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients

Schorling, Ruth Maria; Pfrepper, Christian; Golombek, Thomas; Cella, Chiara Alessandra; Muñoz-Unceta, Nerea; Siegemund, Roland; Engel, Christoph; Petros, Sirak; Lordick, Florian; Knödler, Maren

doi:10.1159/000508271

Cited by 14 publications

(51 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The laboratory findings were evaluated on levels of PLT [(100-300)×10 9 /L], CEA (5 μg/L), CYFRA21-1 (3.3 μg/L), SCC (1.5 μg/L) and LDH (250 U/L). And the patients were classified into normal-, low-, and high-level groups on these levels.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Chen¹,

Li²,

Li³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Tumor-related coagulation dysfunction has been reported to be closely associated with poor prognosis. The present study is aimed to evaluate the prognostic prediction of an elevated plasma D-dimer cut-off value in advanced non-small cell lung cancer (NSCLC).Methods: A total of 233 patients initially diagnosed with advanced NSCLC were retrospectively analyzed, an elevated plasma cut-off value 981 ng/mL of D-dimer, which was instead of the clinical cut-off value 500 mg/mL, was used to determine the high and low. Univariate analysis using the Kaplan-Meier method and log-ranking test, and the multivariate analysis using the Cox proportional hazard regression model were performed.Results: Results showed when using the D-dimer value of 500 ng/mL as an evaluation standard, there was no significant difference in gender, age, smoking status, histopathology and overall survival rate between normal D-dimer (≤500 ng/mL) and high D-dimer (>500 ng/mL) group. However, when the evaluation standard for plasma D-dimer was set at 981 ng/mL, the age distribution of the high D-dimer (>981 ng/mL) group was significantly different from the normal D-dimer (≤981 ng/mL) group. Moreover, the overall survival rate in the high D-dimer (>981 ng/mL) group was significantly lower than that in the normal D-dimer (≤981 ng/mL) group. Conclusions:The present study implied that increasing the plasma D-dimer cut-off value to 981 ng/mL is more beneficial to prognosis prediction in advanced NSCLC.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Plasma D-dimer is a small cross-linked protein generated from fibrin degradation and is an essential indicator of coagulation dysfunction (2,(9)(10)(11). It has critical implications for the exclusion of cancer-related thrombosis clinically (12).…”

Section: Introductionmentioning

confidence: 99%

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Chen¹,

Li²,

Li³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The important decision is the proper time to start anticoagulation, the main concern is that childhood cancer is predisposing for thrombosis (18). Whether early start of anticoagulation for COVID-19 or delay usage as that it might be an immune thrombosis related to neutrophil extracellular traps (19); yet it is acceptable that in both cancer (20) and , D-dimer level is the most important laboratory result in decision for anticoagulation.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in Children with Cancer: A single Low-Middle income center experience

Ebeid

Ragab

Elsherif

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coronavirus disease-2019 (COVID-19) could be associated with morbidity and mortality in immunocompromised children. Objective: To measure the frequency of SARS-COV-2 infection among hospitalized children with cancer and detect the associated clinical manifestations and outcomes. Methodology: A prospective non-interventional study including all hospitalized children with cancer conducted between mid-April and mid-June 2020 in Ain Shams University hospital, Egypt. Clinical, laboratory and radiological data were collected. SARS-CoV2 infection was diagnosed by RT-PCR tests in nasopharyngeal swabs. Results: Fifteen of 61 hospitalized children with cancer were diagnosed with SARS-COV-2. Their mean age was 8.3±3.5 years. Initially, 10(66.7%) were asymptomatic and 5(33.3%) were symptomatic with fever and/or cough. Baseline laboratory tests other than SARS-COV-2 RT-PCR were not diagnostic; the mean absolute lymphocyte count was 8.7±2.4 x109/L, C-reactive protein was mildly elevated in most of patients. Imaging was performed in 10(66.7%) patients with significant radiological findings detected in 4(40%) patients. Treatment was mainly supportive with antibiotics as per the febrile neutropenia protocol and local Children Hospital guidance for management of COVID-19 in children. Conclusion: Pediatric cancer patients with COVID-19 were mainly asymptomatic or with mild symptoms. A high index of suspicion and regular screening with nasopharyngeal swab in asymptomatic hospitalized cancer patients is recommended. Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the first case was detected in December 2019. (1) The COVID-19 pandemic has rapidly escalated into a global crisis. (2) The first case registered in Egypt was in February 2020 and since that date, the numbers have been increasing and by mid-June 2020, 47,856 cases of SARS-CoV-2 and 1766 deaths have been reported by the Ministry of Health (3). Children are usually develops mild disease (4), a Chinese analysis of 2135 confirmed or suspected cases of COVID-19 among children revealed that 55.4% developed mild symptoms or were asymptomatic and only 5.4% had severe illness compared with 18.5% of adult cases. (5) Viral infections in general are associated with increased morbidity and mortality in immunocompromised children. (6) Data on the clinical features and outcomes of immunocompromised children with cancer who are infected with SARS-CoV-2 are scarce. Knowledge from previous influenza A H1N1 pandemics suggests that those vulnerable immunosuppressed children are likely to be infected and to develop manifestation as an increased number of cases are described with time. (7,8) Although isolation as an inpatient is common practice for children who are receiving intensive chemotherapy or stem cell transplant, most children with cancer are treated in the outpatient setting, and hospital visits

show abstract

“…The risk of venous thromboembolism VTE is up to 7-fold higher in cancer patients. 2 Cancer-associated thrombosis (CAT) is the second prevalent cause of mortality in cancer patients. Thromboprophylaxis in ambulatory cancer patients is associated with a 50% decrement of CAT occurrence in a high-risk population, 3 hence the need to stratify patients to high and low risk.…”

Section: Conclusion and Practice Pointsmentioning

confidence: 99%

“…1 Compared to the general population, cancer patients have a 7-times higher risk of thromboembolism. 2 Cancer-associated thrombosis (CAT) is the second most prevalent mortality cause in malignancy patients, following the mortality caused by the direct impact of cancer. 3 Mortality risk increases fourfold with advanced malignancy.…”

Section: Introductionmentioning

confidence: 99%

Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies

Mosaad¹,

Elnaem²,

Cheema³

et al. 2021

IJGM

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients receiving outpatient chemotherapy. The latest guidelines emphasize stratifying the patients in terms of CAT risks periodically. Multiple risk assessment models (RAMs) were developed to classify patients and guide thromboprophylaxis to high-risk patients. This study aimed to discuss and highlight different RAMs across various malignancy types with their related advantages and disadvantages. A scoping review was conducted using predefined search terms in three scientific databases, including Google Scholar, Science Direct, and PubMed. The search for studies was restricted to original research articles that reported risk assessment models published in the last thirteen years (between 2008 and 2021) to cover the most recently published evidence following the development of the principal risk assessment score in 2008. Data charting of the relevant trials, scores, advantages, and disadvantages were done iteratively considering the malignancy type. Of the initially identified 1115 studies, 39 studies with over 67,680 patients were included in the review. In solid organ malignancy, nine risk assessment scores were generated. The first and most known Khorana risk score still offers the best available risk assessment model when used for high-risk populations with a threshold of 2 and above. However, KRS has a limitation of failure to stratify low-risk patients. The COMPASS-CAT score showed the best performance in the lung carcinoma patients who have a higher prevalence of thrombosis than other malignancy subtypes. In testicular germ cell tumours, Bezan et al RAM is a validated good discriminatory RAM for this malignancy subtype. CAT in haematological malignancy seems to be under-investigated and has multiple disease-related, and treatment-related confounding factors. AL-Ani et al score performed efficiently in acute leukemia. In multiple myeloma, both SAVED and IMPEDED VTE scores showed good performance. Despite the availability of different disease-specific scores in lymphoma-related thrombosis, the standard of care needs to be redefined.

show abstract

Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients

Cited by 14 publications

References 38 publications

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

COVID-19 in Children with Cancer: A single Low-Middle income center experience

Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies

Contact Info

Product

Resources

About